Mativ Holdings, Inc. (NYSE:MATV) Stock Position Raised by Invesco Ltd.

Invesco Ltd. grew its position in Mativ Holdings, Inc. (NYSE:MATV - Free Report) by 62.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 943,771 shares of the company's stock after purchasing an additional 364,117 shares during the period. Invesco Ltd. owned approximately 1.74% of Mativ worth $10,287,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Peregrine Capital Management LLC bought a new position in shares of Mativ in the fourth quarter valued at approximately $4,397,000. American Century Companies Inc. boosted its holdings in shares of Mativ by 20.2% in the fourth quarter. American Century Companies Inc. now owns 1,507,418 shares of the company's stock valued at $16,431,000 after acquiring an additional 253,365 shares in the last quarter. Royce & Associates LP boosted its holdings in shares of Mativ by 26.1% in the fourth quarter. Royce & Associates LP now owns 1,090,774 shares of the company's stock valued at $11,889,000 after acquiring an additional 226,090 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Mativ by 44.2% in the fourth quarter. Bank of New York Mellon Corp now owns 613,444 shares of the company's stock valued at $6,687,000 after acquiring an additional 187,970 shares in the last quarter. Finally, Sei Investments Co. boosted its holdings in shares of Mativ by 174.2% in the fourth quarter. Sei Investments Co. now owns 286,992 shares of the company's stock valued at $3,128,000 after acquiring an additional 182,341 shares in the last quarter. Institutional investors own 94.95% of the company's stock.

Analyst Ratings Changes

Separately, Stifel Nicolaus upgraded shares of Mativ from a "hold" rating to a "buy" rating and decreased their price objective for the company from $15.50 to $10.00 in a report on Monday, March 24th.

Mativ Price Performance

NYSE:MATV traded down $0.02 during trading hours on Monday, reaching $5.25. 445,760 shares of the company's stock were exchanged, compared to its average volume of 580,718. The company has a market capitalization of $286.22 million, a P/E ratio of -5.83, a price-to-earnings-growth ratio of 1.08 and a beta of 0.68. Mativ Holdings, Inc. has a 12 month low of $4.34 and a 12 month high of $19.96. The company has a quick ratio of 1.29, a current ratio of 2.40 and a debt-to-equity ratio of 1.28. The business's 50-day simple moving average is $5.88 and its two-hundred day simple moving average is $9.86.

Mativ (NYSE:MATV - Get Free Report) last issued its earnings results on Wednesday, February 19th. The company reported $0.05 earnings per share for the quarter, missing analysts' consensus estimates of $0.22 by ($0.17). The business had revenue of $458.60 million for the quarter, compared to the consensus estimate of $472.70 million. Mativ had a positive return on equity of 3.86% and a negative net margin of 2.46%. Sell-side analysts expect that Mativ Holdings, Inc. will post 1.15 EPS for the current fiscal year.

Mativ Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were issued a dividend of $0.10 per share. This represents a $0.40 dividend on an annualized basis and a yield of 7.62%. The ex-dividend date was Friday, March 14th. Mativ's payout ratio is -44.44%.

About Mativ

Mativ Holdings, Inc, together with its subsidiaries, manufactures and sells specialty materials in the United States, Europe, the Asia Pacific, the Americas, and internationally. The company operates through two segments, Advanced Technical Materials and Fiber-Based Solutions. The Advanced Technical Materials manufactures and sells various engineered polymer, resin and fiber-based substrates, nets, films, adhesive tapes, and other nonwovens for the filtration, protective solutions, release liners, and healthcare end-markets.